[{"NetIncomeLoss_1_Q2_USD":-198780.0,"AssetsCurrent_0_Q2_USD":1632652.0,"FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_2_Q2_USD":0.0,"NetCashProvidedByUsedInInvestingActivities_1_Q2_USD":-149500000.0,"AccruedLiabilitiesCurrent_0_Q2_USD":139835.0,"CommitmentsAndContingencies_0_Q2_USD":null,"GeneralAndAdministrativeExpense_1_Q2_USD":185367.0,"PreferredStockSharesOutstanding_0_Q2_shares":0.0,"ProceedsFromRelatedPartyDebt_1_Q2_USD":250000.0,"GainLossOnInvestments_1_Q2_USD":-13413.0,"Liabilities_0_Q2_USD":5638278.0,"Cash_0_Q2_USD":1263136.0,"IncreaseDecreaseInAccountsPayable_1_Q2_USD":3665.0,"PaymentsOfStockIssuanceCosts_1_Q2_USD":3280743.0,"FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_2_Q2_USD":0.0,"FairValueAssetsLevel2ToLevel1TransfersAmount_0_Q2_USD":0.0,"NetCashProvidedByUsedInFinancingActivities_1_Q2_USD":151209257.0,"ProceedsFromIssuanceOfPrivatePlacement_1_Q2_USD":4990000.0,"AssetsHeldInTrustNoncurrent_0_Q2_USD":149486587.0,"OtherNonoperatingIncomeExpense_1_Q2_USD":-13413.0,"IncreaseDecreaseInPrepaidExpensesOther_1_Q2_USD":369516.0,"TemporaryEquitySharesOutstanding_0_Q2_shares":14048096.0,"TemporaryEquityCarryingAmountAttributableToParent_0_Q2_USD":140480960.0,"RepaymentsOfRelatedPartyDebt_1_Q2_USD":250000.0,"PreferredStockSharesIssued_0_Q2_shares":0.0,"AdditionalPaidInCapital_0_Q2_USD":5233005.0,"AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_1_Q2_USD":8800521.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q2_USD":1263136.0,"AccountsPayableCurrent_0_Q2_USD":265943.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_1_Q2_USD":1263136.0,"LiabilitiesCurrent_0_Q2_USD":405778.0,"NetCashProvidedByUsedInOperatingActivities_1_Q2_USD":-446121.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-233518.0,"IncreaseDecreaseInAccruedLiabilities_1_Q2_USD":139835.0,"TemporaryEquityRedemptionPricePerShare_0_Q2_USD":10.0,"PreferredStockSharesAuthorized_0_Q2_shares":1000000.0,"LiabilitiesAndStockholdersEquity_0_Q2_USD":151119239.0,"PreferredStockValue_0_Q2_USD":0.0,"ProceedsFromIssuanceInitialPublicOffering_1_Q2_USD":149500000.0,"OperatingIncomeLoss_1_Q2_USD":-185367.0,"FairValueAssetsLevel1ToLevel2TransfersAmount_0_Q2_USD":0.0,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.0001,"PreferredStockParOrStatedValuePerShare_0_Q2_USD":0.0001,"Assets_0_Q2_USD":151119239.0,"StockholdersEquity_0_Q2_USD":5000001.0,"PrepaidExpenseCurrent_0_Q2_USD":369516.0,"Ticker":"CERE","CIK":"1805387","name":"ARYA SCIENCES ACQUISITION CORP II","OfficialName":"Cerevel Therapeutics Holdings Inc. Common Stock","form":"10-Q","period":"20200630","fy":"2020.0","fp":"Q2","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"4823550476.0","Country":"United States","Sector":"Consumer Durables","Industry":"Specialty Chemicals","Market":"NASDAQ","SP500":"nan","filed":"20200814"}]